Alkyl amines chemicals Limited has completed the allotment of 75 equity shares to eligible employees under its Employee Stock Option Plan 2018 (ESOP-2018) on December 19, 2025. The allotment was approved through a circular resolution passed by the Nomination and Remuneration Committee of the Board of Directors on the same date.

Share Allotment Details

The company allotted 75 equity shares with a face value of ₹2.00 each to eligible employees upon exercise of stock options granted under the AACL-ESOP 2018 scheme. This allotment represents the execution of previously granted employee stock options under the company's established employee benefit program.

Impact on Share Capital

The allotment has resulted in a marginal increase in the company's paid-up equity share capital. The capital structure has been updated to reflect the new share issuance under the employee stock option plan.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification has been filed with both BSE (scrip code: 506767) and NSE (symbol: ALKYLAMINE) as required under SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

The original ESOP-2018 scheme filing dates were February 2, 2019 for BSE and February 4, 2019 for NSE. No lock-in period applies to these allotted shares, and they will rank pari passu with existing equity shares of the company.

Listing and Fee Structure

Since the company's paid-up capital remains within the ₹100 crores slab, no additional listing fees are payable for the newly issued equity shares. The company has already paid the requisite listing fees for this capital range, covering the current allotment under the existing fee structure.

The allotment demonstrates the company's commitment to its employee incentive programs while maintaining compliance with all regulatory requirements for listed entities.

Alkyl Amines Chemicals Limited (AACL) has initiated a postal ballot process to seek shareholder approval for a revision in the remuneration of its Whole-time Director-Operations, Mr. Rakesh S. Goyal. The key proposal is to increase his commission from 0.10% to 0.30% of net profits, effective January 1, 2026.

Proposed Remuneration Changes

The company plans to modify Mr. Goyal's compensation structure as follows:

Other components of Mr. Goyal's remuneration package, which were effective from April 1, 2025, will remain unchanged. These include:

• Basic Salary: Rs. 6,00,000 to Rs. 7,20,000 per month with annual increments of Rs. 60,000 per month
• House Rent Allowance: 40% of basic salary
• Other benefits: Leave Travel Assistance, Mediclaim Policy Premium, Provident Fund, Gratuity, and additional perks as per company policy

Voting Process

AACL has outlined the following schedule for the postal ballot:

• E-voting Period: November 21, 2025 to December 20, 2025
• Result Declaration: By December 23, 2025

The company has engaged National Securities Depository Limited (NSDL) to provide the e-voting facility to its shareholders.

Rationale and Approval Process

The proposed revision aims to align Mr. Goyal's compensation with industry standards, considering his 30 years of experience in manufacturing, technology transfer, process development, quality management, and sales and marketing. The Nomination and Remuneration Committee approved this change on October 23, 2025, followed by the Board of Directors' approval on November 4, 2025.

Mr. Goyal, who holds 12,295 equity shares (0.02% of the company's paid-up equity share capital), is not related to any other Director on the Board. He has attended all Board meetings in the current financial year and serves as a member of the Risk Management Committee.

Shareholders are encouraged to participate in the e-voting process to voice their decision on this proposed remuneration change for a key executive of Alkyl Amines Chemicals Limited.